Nitrates Updated

Current Use in Angina, Ischemia, Infarction and Failure

  • Udho Thadani
  • Lionel H. Opie

Table of contents

  1. Front Matter
    Pages i-x
  2. Kristina E. Torfgård, Johan Ahlner
    Pages 21-56
  3. Ho-Leung Fung, John Anthony Bauer
    Pages 57-79
  4. Marc G. Bogaert
    Pages 80-93
  5. Udho Thadani, Raymond J. Lipicky
    Pages 94-116
  6. Udho Thadani, Lionel H. Opie
    Pages 134-149
  7. Bodh I. Jugdutt
    Pages 150-174
  8. Henry Purcell, David Mulcahy, Kim Fox
    Pages 175-190
  9. Jocelyn Dupuis
    Pages 191-203
  10. Back Matter
    Pages 217-224

About this book


Nitrates remain among the most commonly used therapeutic agents in cardiology. That they can re­ lieve pain in angina pectoris has been known at least since 1867, when Lauder Brunton described their clinical use. Now, almost 130 years later, we are constantly learning more about their optimal use in anginal syndromes. For example, there is no doubt that nitrate tolerance occurs, but equally no doubt that certain drug dosages help to attenuate such toler­ ance. Thus, our understanding of nitrate tolerance has been taken further by the advent of new nitrate preparations and by studies at a basic science level. The current intense interest in nitrates has been rekindled by the growing emphasis on the role of the endothelium in the production of nitric oxide, a basic cardiovascular regulator. If nitric oxide is vasodilator and protects the vascular endothelium, then nitrates should also have similar properties. Hence this book starts off with the role of the endothelium and ni­ trates in vasodilation. Next, the mechanisms of ac­ tion of nitrates are considered with emphasis on the role of cyclic GMP. The chief limitation to the use of nitrates lies in nitrate tolerance. After carefully looking at all the evidence, the authors of the third chapter conclude that the mechanism is likely to be multifactorial. The mechanism responsible for the tolerance still remains unknown. In vitro tolerance may be due to enhanced production of vascular superoxide [1].


angina pectoris cardiovascular drugs heart heart disease heart failure myocardial infarction

Editors and affiliations

  • Udho Thadani
    • 1
  • Lionel H. Opie
    • 2
    • 3
  1. 1.Health Sciences CenterUniversity of OklahomaOklahoma CityUSA
  2. 2.University of Cape TownCape TownSouth Africa
  3. 3.Division of CardiologyStanford University Medical CenterStanfordUSA

Bibliographic information